Department of Hematology, Oncology and Cancer Immunology, Charité─Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, D-12203 Berlin, Germany.
Faculty of Pharmacy, University of Ljubljana, Aškerčeva Cesta 7, SI-1000 Ljubljana, Slovenia.
J Med Chem. 2023 Apr 13;66(7):4703-4733. doi: 10.1021/acs.jmedchem.2c01817. Epub 2023 Mar 30.
Proteolysis targeting chimeras (PROTACs) represent a new pharmacological modality to inactivate disease-causing proteins. PROTACs operate via recruiting E3 ubiquitin ligases, which enable the transfer of ubiquitin tags onto their target proteins, leading to proteasomal degradation. However, several E3 ligases are validated pharmacological targets themselves, of which inhibitor of apoptosis (IAP) proteins are considered druggable in cancer. Here, we report three series of heterobifunctional PROTACs, which consist of an IAP antagonist linked to either von Hippel-Lindau- or cereblon-recruiting ligands. Hijacking E3 ligases against each other led to potent, rapid, and preferential depletion of cellular IAPs. In addition, these compounds caused complete X-chromosome-linked IAP knockdown, which was rarely observed for monovalent and homobivalent IAP antagonists. In cellular assays, hit degrader outperformed antagonists and showed potent inhibition of cancer cell viability. The hetero-PROTACs disclosed herein are valuable tools to facilitate studies of the biological roles of IAPs and will stimulate further efforts toward E3-targeting therapies.
蛋白水解靶向嵌合体(PROTACs)代表了一种使致病蛋白失活的新型药理学模式。PROTACs 通过招募 E3 泛素连接酶来发挥作用,使泛素标签转移到其靶蛋白上,导致蛋白酶体降解。然而,有几种 E3 连接酶本身就是经过验证的药理学靶点,其中凋亡抑制蛋白(IAP)被认为是癌症治疗的药物靶点。在这里,我们报告了三个系列的杂双功能 PROTACs,它们由 IAP 拮抗剂与 von Hippel-Lindau 或 cereblon 招募配体连接而成。相互劫持 E3 连接酶导致细胞 IAP 的快速、强效且优先耗尽。此外,这些化合物导致完全的 X 染色体连锁 IAP 敲低,而单价和同型双价 IAP 拮抗剂很少观察到这种情况。在细胞测定中,命中降解剂优于拮抗剂,并显示出对癌细胞活力的有效抑制。本文公开的杂 PROTACs 是促进 IAP 生物学作用研究的有用工具,并将激发对 E3 靶向治疗的进一步努力。